Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

11.1%

57 terminated/withdrawn out of 515 trials

Success Rate

88.8%

+2.3% vs industry average

Late-Stage Pipeline

43%

223 trials in Phase 3/4

Results Transparency

18%

82 of 452 completed trials have results

Key Signals

2 recruiting82 with results51 terminated6 withdrawn

Enrollment Performance

Analytics

Phase 3
202(41.3%)
Phase 1
150(30.7%)
Phase 2
110(22.5%)
Phase 4
21(4.3%)
N/A
6(1.2%)
489Total
Phase 3(202)
Phase 1(150)
Phase 2(110)
Phase 4(21)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (515)

Showing 20 of 515 trials
NCT06085586Not ApplicableRecruiting

Fibulink Syndesmosis Repair System With Early Full-Weight Bearing

Role: collaborator

NCT03881098Not ApplicableRecruiting

The Lung PCA: A Multi-Dimensional Atlas of Pulmonary Premalignancy

Role: collaborator

NCT04693793Not ApplicableCompleted

Establishing Clinical Utility for a New Diagnostic Test for Patients With Shortness of Breath

Role: collaborator

NCT04330248Phase 1Completed

A Study of Steady-state Carbamazepine on the Single-dose of Erdafitinib Tablets in Healthy Adult Participants

Role: lead

NCT04850911Not ApplicableUnknown

Reward Emotion Learning and Ketamine Study

Role: collaborator

NCT01060254Phase 2Terminated

A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain

Role: lead

NCT00256776Phase 3Terminated

MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation

Role: collaborator

NCT01821508Not ApplicableCompleted

Clinical Study on Metabolic Surgery Compared to the Best Clinical Treatment in Patients With Type 2 Diabetes Mellitus

Role: collaborator

NCT02677207Phase 2Completed

The Effects of JNJ-39393406 on Psychometric Performance and Residual Depressive

Role: collaborator

NCT00973141Phase 2Terminated

A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain

Role: lead

NCT01094262Phase 2Terminated

A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis

Role: lead

NCT00472303Phase 3Completed

A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine

Role: collaborator

NCT00505414Phase 3Terminated

A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine

Role: collaborator

NCT00478023Phase 3Completed

A Study to Evaluate the Efficacy and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain After Abdominal Hysterectomy

Role: collaborator

NCT00486811Phase 3Completed

A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

Role: collaborator

NCT03979989Phase 1Completed

Drug-drug Interaction Study to Evaluate the Effect of Omeprazole on CG5503 (Tapentadol)

Role: collaborator

NCT00096408Phase 3Completed

Laparoscopic Approach to Cancer of the Endometrium

Role: collaborator

NCT00515034Phase 2Completed

A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia

Role: lead

NCT01756404Phase 1Completed

Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers

Role: lead

NCT00722137Phase 3Completed

Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma

Role: collaborator